FDA to Stop Enforcing Premarket Approval for Replacement Heart Valve Allografts

Summary

The FDA has announced that it will no longer enforce the premarket approval requirement for replacement heart valve allografts, allowing these devices to be commercially distributed without prior approval. The agency plans to classify these devices as Class II, citing the potential for special controls to ensure their safety and effectiveness.